Gardasil 9 (human papillomavirus 9-valent vaccine, recombinant)

P3, N=700, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2029 --> Oct 2029 | Trial primary completion date: Jun 2029 --> Oct 2029

P1, N=72, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2027 --> Aug 2027 | Trial primary completion date: Feb 2027 --> Aug 2027

P4, N=250, Recruiting, Louisiana State University Health Sciences Center in New Orleans | N=150 --> 250 | Trial completion date: Mar 2025 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Dec 2025

P4, N=450, Recruiting, University of British Columbia | Phase classification: P3 --> P4 | Trial completion date: Aug 2026 --> Jan 2028 | Trial primary completion date: Aug 2024 --> Aug 2026

P3, N=6033, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Sep 2026 --> Aug 2028 | Trial primary completion date: Sep 2026 --> Aug 2027

P1, N=72, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Apr 2026 --> Aug 2027 | Trial primary completion date: Apr 2026 --> Aug 2027

P3, N=1990, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

P4, N=97, Active, not recruiting, Fred Hutchinson Cancer Center | Trial completion date: Oct 2026 --> Jul 2026 | Trial primary completion date: Sep 2026 --> Jun 2026

P4, N=372, Completed, McGill University | Active, not recruiting --> Completed | N=1000 --> 372

P2, N=35, Not yet recruiting, Northern Jiangsu People's Hospital

P3, N=700, Active, not recruiting, Weill Medical College of Cornell University | Trial primary completion date: Apr 2026 --> Nov 2025

P2, N=120, Not yet recruiting, University of Maryland, Baltimore | N=180 --> 120

P2, N=85, Recruiting, Centre Oscar Lambret | Not yet recruiting --> Recruiting | Initiation date: Oct 2024 --> Jan 2025

P=N/A, N=610, Recruiting, University of Alabama at Birmingham | Trial completion date: Jul 2025 --> Jun 2026 | Trial primary completion date: Feb 2025 --> Dec 2025

P1/2, N=1080, Completed, GlaxoSmithKline | Trial completion date: Jun 2024 --> Feb 2024

P4, N=100, Not yet recruiting, Emory University

P2, N=100, Not yet recruiting, Vastra Gotaland Region

P3, N=1990, Merck Sharp & Dohme LLC

P1, N=72, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

P=N/A, N=219, Completed, Liaquat University of Medical & Health Sciences

P4, N=750, Recruiting, Massachusetts General Hospital | Not yet recruiting --> Recruiting

P=N/A, N=219, Completed, Liaquat University of Medical & Health Sciences

P4, N=352, Active, not recruiting, Boston Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> Aug 2025

P2, N=54, Active, not recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting --> Active, not recruiting | N=100 --> 54

P3, N=8100, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Nov 2024 --> May 2029

P2, N=100, Recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P2, N=180, Not yet recruiting, University of Maryland, Baltimore | Initiation date: Oct 2024 --> Feb 2025

SCT1000 elicited robust, durable, and consistent humoral immune responses across all 14 HPV types, indicating its potential as a broad-spectrum vaccine candidate against HPV types 6/11/16/18/31/33/35/39/45/51/52/56/58/59. The significant correlations observed between PBNA and total IgG LIA support the use of the Luminex-based total IgG method as a reliable and effective alternative for immunogenicity assessment in preclinical and future clinical vaccine development.

P1, N=26, Terminated, National Cancer Institute (NCI) | Completed --> Terminated; Study closed due to low accrual.

P1, N=72, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

P1, N=72, Not yet recruiting, Merck Sharp & Dohme LLC

P1/2, N=1080, Completed, GlaxoSmithKline | Active, not recruiting --> Completed | Phase classification: P2 --> P1/2

P=N/A, N=392, Active, not recruiting, Xiamen University | Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

P4, N=1403, Completed, Columbia University | Active, not recruiting --> Completed

P4, N=360, Recruiting, Boston Medical Center | Trial completion date: Sep 2025 --> Dec 2025

P2, N=85, Not yet recruiting, Centre Oscar Lambret

P1, N=150, Active, not recruiting, Boston Medical Center | Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2028 --> Jul 2028

Our research confirms a widespread HR-HPV infection in our population and extends the importance of studies on the molecular prevalence of HPV, particularly in women with normal cytology and apparent good health, in view of the cruel lack of public awareness of HPV infections.

P2, N=180, Not yet recruiting, University of Maryland, Baltimore

P1, N=72, Not yet recruiting, Merck Sharp & Dohme LLC

P4, N=30, Recruiting, Medical College of Wisconsin | N=100 --> 30

In Greece, we observed a high HPV-AF (52.1%) in OPC, approximating the AFs reported for some Northern European countries. HPV+ versus HPV- patients were younger, more frequently with tonsillar tumors, and less frequently at TNM stage IV. Since most patients were infected by ≥1 HPV type targeted by the 9-valent vaccine, the HPV+ OPC burden could be mitigated through a routine HPV gender-neutral vaccination program.